🚀 Exciting News! Pharmidex Launches Comprehensive Histology Services! 🔬✨
March 6, 2025

We’re expanding our capabilities with state-of-the-art histotechnology, delivering high-quality, rapid tissue analysis across dermatology, respiratory, toxicology, oncology, and CNS research.


🔎 What We Offer:

✅ High-Throughput Processing – Fast & reliable for large sample volumes

✅ Expert Paraffin Embedding & Sectioning – Precision tissue preservation

✅ Advanced Staining & Immunohistochemistry – Routine & specialized stains for in-depth analysis

✅ Digital Imaging & Slide Scanning – High-resolution visualizations for detailed examination


⚡ Why Choose Pharmidex?

✔️ Cutting-edge technology

✔️ Stringent quality control

✔️ Seamless sample-to-slide traceability


Let’s advance histology together! Get in touch to explore how we can support your research.


🔗 Learn more: pharmidex.com/histology

#Pharmidex #Histology #TissueAnalysis #DrugDiscovery #LifeSciences #Innovation

June 11, 2025
Pharmidex team are delighted to participate in workshop on "Re-shaping UK life science commercialisation strategy" organised by The Research and Development Society on Wednesday 11th June, at Mereside, Alderley Park. If you are attending, please linkup with our colleague Mo Alavijeh who will be delighted to meet you. Jamie Phadke , Alderley Park #UKlifescience https://lnkd.in/e6uKsRcN
June 10, 2025
Martin Barrett , Head of Business Development, will attend the symposium on 10–13 June 2025 at Hotel Comwell Borupgaard, Denmark. The event gathers top European scientists to discuss drug discovery. Martin looks forward to connecting with academia, CROs, and pharma to explore collaborations and showcase Pharmidex’s services from in silico to in vivo pharmacology. Attending? Let’s connect! 🔗 https://lnkd.in/ev7TW7WG
June 10, 2025
We’re excited to announce our involvement in the recent publication: "Anti-Inflammatory Activity of Ensifentrine: A Novel, Selective Dual Inhibitor of PDE3 and PDE4" 📄 https://pubmed.ncbi.nlm.nih.gov/40245851/ 📄 https://www.pharmidex.com/publications-by-pharmidex Dr. Radhakrishnan Venkatasamy , our Senior Scientist in autoinflammatory and immune diseases, co-authored this study highlighting Ensifentrine’s anti-inflammatory potential. This reflects Pharmidex’s commitment to advancing therapies through expert science and collaboration.
More Posts